Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir plus 2 NRTIs in HIV-infected solid organ transplant recipients
2017-000469-62Phase 4Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir, abacavir, lamivudine, emtricitabine and tenofovir in Human immunodeficiency virus infection type 1, sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Pharmacokinetic interactions between dolutegravir and immunosuppressants. Started Jun 2017; status: completed.
02
Drugs
dolutegravirabacavirlamivudineemtricitabinetenofovir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2017-000469-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000469-62.